ALTIMMUNE INC (ALT:NASDAQ)
$2.84 -0.14 (-4.698%)
Analysed ALTIMMUNE INC (ALT:NASDAQ) News Sources
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
25-06-2026
yahoo.com
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
26-06-2026
yahoo.com
Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market
05-07-2026
yahoo.com
US Research house initiates Solvonis coverage citing differentiated addiction strategy
13-07-2026
proactiveinvestors.com
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
28-07-2026
yahoo.com
Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results
28-07-2026
advfn.com
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%
28-07-2026
stocktwits.com
Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial
28-07-2026
marketbeat.com
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff
28-07-2026
stocktwits.com
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
29-07-2026
biopharmadive.com
What is the current price of ALTIMMUNE INC (ALT:NASDAQ)?
The current price of ALTIMMUNE INC (ALT:NASDAQ) is $2.84.
ALTIMMUNE INC (ALT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALTIMMUNE INC (ALT:NASDAQ) since the previous trading day is $-0.14.
ALTIMMUNE INC (ALT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALTIMMUNE INC (ALT:NASDAQ) since the previous trading day is -4.698%.
What is the most recent average sentiment score for ALTIMMUNE INC (ALT:NASDAQ)?
The most recent average sentiment score for ALTIMMUNE INC (ALT:NASDAQ) is 54 out of 100.
What is the most recent average sentiment for ALTIMMUNE INC (ALT:NASDAQ)?
The most recent sentiment for ALTIMMUNE INC (ALT:NASDAQ) is .
SEC-8K** Filing Available For ALTIMMUNE INC (ALT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.